CN100356943C - Medicinal composition for treating diabetes - Google Patents
Medicinal composition for treating diabetes Download PDFInfo
- Publication number
- CN100356943C CN100356943C CNB2005100272736A CN200510027273A CN100356943C CN 100356943 C CN100356943 C CN 100356943C CN B2005100272736 A CNB2005100272736 A CN B2005100272736A CN 200510027273 A CN200510027273 A CN 200510027273A CN 100356943 C CN100356943 C CN 100356943C
- Authority
- CN
- China
- Prior art keywords
- rhizoma polygoni
- polygoni cuspidati
- extract
- ethyl acetate
- gets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicinal composition for treating diabetes, particularly to a medicinal composition using Chinese herb extract as raw materials. The composition has the following compositions of weight percentage: 48 to 57 wt% of giant knotweed extract, 18 to 25 wt% of mulberry leaf extract and 22 to 33 wt% of atrichum extract. The medicinal composition for treating diabetes of the present invention has the action of obviously reducing postprandial blood sugar of mice and blood sugar of mice with alloxan diabetes, and the medicinal composition can be applied to prevent and treat the diabetes and complicating diseases thereof.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of diabetes, particularly a kind of is the pharmaceutical composition of raw material with the Chinese herbal medicine extract.
Background technology
Diabetes are a kind of common chronic endocrine and metabolic disorders diseases, and its sickness rate (mainly being type ii diabetes) rises year by year, and mortality rate has occupied the 3rd after tumor and the cardiovascular disease.Orally-taken blood sugar reducing medicine therapy is adopted in the treatment of type ii diabetes more, the orally-taken blood sugar reducing medicine that is used for the treatment of at present type ii diabetes clinically has the sulfonylureas drugs for diabetes thing, biguanide antidiabetic medicament, and alpha-glucosidase inhibitor class medicine, but because the strong side effect of sulphanylureas and biguanides (damages pancreatic beta cell, hypoglycemia etc. as sulphanylureas; Lactic acidosis etc. easily takes place in biguanides), its use has been subjected to certain limitation.
Summary of the invention
Purpose of the present invention just is to provide a kind of Pharmaceutical composition with treatment diabetes of remarkable physiological effect.
At present, the method of treatment diabetes is to adopt alpha-glucosidase inhibitor, the effect of alpha-glucosidase inhibitor is to be present in hydrolytic enzyme activities such as the maltase on human small intestine's mucosa microvillose membrane surface and saccharase by regulation and control, block saccharide compound and resolved into the process of monosaccharide such as glucose, delayed digesting and assimilating of carbohydrate, thereby can avoiding after meal, blood glucose rises rapidly, suppress post-prandial hyperglycemia and insulin excessive secretion, reduce patient's blood glucose fluctuation amplitude, reach good control blood glucose.The extract of conventional medicament and plant such as Rhizoma Polygoni Cuspidati, Folium Mori, Herba Agrimoniae all has intensive alpha-glucosidase and suppresses active, and the extracting section thing also has significant aldose reductase inhibition activity.Confirm through clinical trial, it is the one of the main reasons that causes chronic complicating diseases of diabetes that aldose reductase activity increases, suppress the activity of aldose reductase, can improve the polyhydric alcohol metabolism disorder of diabetics effectively, thus the generation of prevention and delay diabetic complication.Through hypoglycemic activity in the body of these extracts is studied, find that these extracts all can reduce the blood glucose of alloxan diabetes mouse model to some extent, and different extracts there is visibly different model of action.
Rhizoma Polygoni Cuspidati (Polygonum cuspidatum Sieb, et Zucc) is the Polygonaceae arsesmart, has another name called speckle root Radix dactylicapni (Radix Dactylicapnotis), the dragon of invigorating blood circulation, Rhizoma Polygoni Cuspidati etc.Medicinal part is a rhizome, the analgesic therapy of invigorating blood circulation, clearing away heat-damp and promoting diuresis, detoxifcation, effect such as antibacterial.Be mainly used in the multiple infectious disease of treatment, burn, microcirculation dysfunction, tumor etc. clinically, do not find toxic and side effects.Main chemical compositions has: emodin, chrysophanol, resveratrol (resveratrol), polidatin (polydatin, or claim Rhizoma Polygoni Cuspidati brilliant IV), Quercetin (quercetin), protocatechuic acid (protocatechuicacid), glucosides class, aminoacid etc., and be rich in condensed tannin and polysaccharide.The Rhizoma Polygoni Cuspidati tannic acid can reach the good control to post-prandial glycemia by the glycosidase activity on regulation and control human small intestine mucosa microvillose membrane surface; Emodin can be prevented and treated the early stage kidney damage of the inductive diabetes rat of STZ (streptozotocin), and its mechanism may suppress the synthetic of ET-1 (Endothelin) etc. and discharge; The Rhizoma Polygoni Cuspidati resveratrol is by removing interior free yl, suppressing lipid peroxidation, reaches blood fat reducing, antioxidation, blood sugar lowering and improves the effect of diabetic complication.
Folium Mori different name Herba adianti myriosori is the leaves of Moraceae Morus Morus alba L. (medical material Folium Mori).Main chemical compositions has: flavonoid, steroid class, polysaccharide and aminoacid etc.The medicinal head of Folium Mori is stated from Shennong's Herbal, and Folium Mori bitter but sweet flavor, cold is the key medicine of traditional Chinese medical science heat-clearing and toxic substances removing.Disease such as cure mainly that hotness is emitted, lung-heat type cough, dizzy headache, conjunctival congestion are dizzy, clinical practice is very extensive, and Folium Mori commonly used are used as medicine, and form herbal mixture, and curative effect is good.The Morus plant has multiple biological activitys such as blood sugar lowering, blood pressure lowering, antibiotic and antiviral.Modern pharmacological research proves; the remarkable effect of flavones in mulberry leaves to reducing alloxan diabetes mice hyperglycemia, improving its carbohydrate tolerance; may be by the absorption that suppresses disaccharidase, slows down the small intestinal glucose; antioxidation, reduce the diabetes rat oxidative damage, and protection spleen antioxidase, improve that mechanism such as splenic function realizes.
Herba Agrimoniae is a Radix Agrimoniae, Rosaceae.Perennial herb is by hair.Be distributed in the Northern Hemisphere, China all produces various places.With all herbal medicine, slightly warm in nature, bitter and puckery flavor, function hemostasis cures mainly haematemesis, has blood in stool, diseases such as hematuria, metrorrhagia.Herb contains compositions such as agrimonine, tannin, sterol, organic acid, phenolic constituent and agrimonolide.The Herba Agrimoniae flavone has glycosidase activity in the regulation and control body, suppresses the effect of protein non-enzyme glycosylation under the high sugared environment.
These three kinds of extracts according to the pharmacology principle, through scientific matching and combination, are had complementary functions to reach, and its action effect will be more obvious.
According to above-mentioned mechanism, the present invention adopts following technical scheme:
A kind of pharmaceutical composition that is used for the treatment of diabetes is characterized in that the constituent of said composition and weight percent proportioning thereof are as follows:
Rhizoma Polygoni Cuspidati extract 48-57%
Folium Mori extract 18-25%
Herba Agrimoniae extract 22-33%;
Wherein said Rhizoma Polygoni Cuspidati extract is that main active ingredient is that the Rhizoma Polygoni Cuspidati extract 1 of Rhizoma Polygoni Cuspidati tannic acid, main active ingredient are the Rhizoma Polygoni Cuspidati extract 2 of Rhizoma Polygoni Cuspidati resveratrol and Rhizoma Polygoni Cuspidati extract 3 that main active ingredient is the Rhizoma Polygoni Cuspidati emodin mixture with the weight ratio of 20-25: 60-65: 14-16; The main active ingredient of described Folium Mori extract is a flavones in mulberry leaves; The main active ingredient of described Herba Agrimoniae extract is the Herba Agrimoniae flavone;
The extracting method of described Rhizoma Polygoni Cuspidati extract 1 is: Rhizoma Polygoni Cuspidati rhizome coarse powder, 95% ethanol merceration, cooling bath filters, concentrating under reduced pressure gets extractum, use chloroform reflux extraction after adding water, back water liquid ethyl acetate extraction, the precipitation that ethyl acetate layer produces in the filtering extraction process, ethyl acetate layer NaOH aqueous solution extraction, the NaOH aqueous solution is regulated pH to 4 with rare HCl, and adding 5% aqueous gelatin solution must precipitate, precipitation adds 50% acetone solution, the centrifugal acetone soln that gets, acetone, water liquid ethyl acetate extraction are reclaimed in distilling under reduced pressure, ethyl acetate is reclaimed in the ethyl acetate layer distilling under reduced pressure, add the suitable quantity of water dissolving, the elimination precipitation, concentrate drying gets inhibitor crude product (orange-yellow powder), the inhibitor crude product is made into 10mg/ml goes up the HZ802 macroporous adsorbent resin, with 70% ethanol water eluting.Collect active component, concentrate, dry orange-yellow inhibitor powder.Main active is the Rhizoma Polygoni Cuspidati tannic acid;
The extracting method of described Rhizoma Polygoni Cuspidati extract 2 is: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (4: 6), and the some plate is followed the tracks of active substance, will have active substance partly to merge and cross silicagel column for the second time, mobile phase is constant, collect active component, drying gets white powder, and active site is the Rhizoma Polygoni Cuspidati resveratrol;
The extracting method of described Rhizoma Polygoni Cuspidati extract 3 is: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (3: 7), and the some plate is followed the tracks of active substance, will have active substance partly to merge after silicagel column, mobile phase changes chloroform into, collect active component, drying gets pale yellow powder, and active site is the Rhizoma Polygoni Cuspidati emodin;
The extracting method of described Folium Mori extract is: the Folium Mori dry product, pulverize, and alcohol reflux 4 hours, 4000rpm gets supernatant, concentrates the back adding distil water, the centrifuging and taking supernatant, petroleum ether extraction gets water alcohol liquid.Last D101 adsorbent resin is washed to colourlessly, and the back is eluted to colourlessly with dehydrated alcohol, and concentrate drying promptly gets Folium Mori extract, and active site is a flavones in mulberry leaves;
The extracting method of described Herba Agrimoniae extract is: the Herba Agrimoniae coarse powder, 40% ethanol lixiviate 3 times, filter to get filtrate, concentrate, water alcohol method is removed chlorophyll, centrifugal marriage supernatant, petroleum ether extraction, water intaking alcohol layer concentrates the back and goes up the D101 macroporous adsorbent resin, the dehydrated alcohol eluting gets Herba Agrimoniae extract, and active site is the Herba Agrimoniae flavone.
Above-mentioned a kind of pharmaceutical composition that is used for the treatment of diabetes is used in the preparation hypoglycemic drug.
The above-mentioned a kind of application of pharmaceutical composition in preparation treatment diabetes medicament that is used for the treatment of diabetes.
Compare with prior art, adopt the pharmaceutical composition that is used for the treatment of diabetes of the present invention to have the effect of remarkable reduction mice post-prandial glycemia and alloxan diabetes mouse blood sugar, can be applicable to prevention and treatment diabetes and complication thereof.
Description of drawings
Fig. 1 is amount of composition and inhibitor graph of a relation
Fig. 2 pharmaceutical composition is to the design sketch of mice post-prandial glycemia influence
The specific embodiment
The preparation method of the Rhizoma Polygoni Cuspidati that the present invention adopts, Folium Mori, Herba Agrimoniae extract is as follows:
Main active is the Rhizoma Polygoni Cuspidati extract 1 of Rhizoma Polygoni Cuspidati tannic acid: Rhizoma Polygoni Cuspidati rhizome coarse powder, 95% ethanol merceration, cooling bath filters, concentrating under reduced pressure gets extractum, use chloroform reflux extraction after adding water, back water liquid ethyl acetate extraction, the precipitation that ethyl acetate layer produces in the filtering extraction process, ethyl acetate layer NaOH aqueous solution extraction, the NaOH aqueous solution is regulated pH to 4 with rare HCl, and adding 5% aqueous gelatin solution must precipitate, precipitation adds 50% acetone solution, the centrifugal acetone soln that gets, acetone, water liquid ethyl acetate extraction are reclaimed in distilling under reduced pressure, ethyl acetate is reclaimed in the ethyl acetate layer distilling under reduced pressure, add the suitable quantity of water dissolving, the elimination precipitation, concentrate drying gets inhibitor crude product (orange-yellow powder), the inhibitor crude product is made into 10mg/ml goes up the HZ802 macroporous adsorbent resin, with 70% ethanol water eluting.Collect active component, concentrate, dry orange-yellow inhibitor powder.Main active is the Rhizoma Polygoni Cuspidati tannic acid.
Main active is the Rhizoma Polygoni Cuspidati extract 2 of Rhizoma Polygoni Cuspidati resveratrol: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (4: 6), and the some plate is followed the tracks of active substance, will have active substance partly to merge and cross silicagel column for the second time, mobile phase is constant, collect active component, drying gets white powder, and active site is the Rhizoma Polygoni Cuspidati resveratrol.
Main active is the Rhizoma Polygoni Cuspidati extract 3 of Rhizoma Polygoni Cuspidati emodin: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (3: 7), and the some plate is followed the tracks of active substance, will have active substance partly to merge after silicagel column, mobile phase changes chloroform into, collect active component, drying gets pale yellow powder, and active site is the Rhizoma Polygoni Cuspidati emodin.
2, Folium Mori extract: the Folium Mori dry product, pulverize, alcohol reflux 4 hours, 4000rpm gets supernatant, concentrates the back adding distil water, the centrifuging and taking supernatant, petroleum ether extraction gets water alcohol liquid.Last D101 adsorbent resin is washed to colourlessly, and the back is eluted to colourlessly with dehydrated alcohol, and concentrate drying promptly gets Folium Mori extract, and active site is a flavones in mulberry leaves.
3, Herba Agrimoniae extract: Herba Agrimoniae coarse powder, 40% ethanol lixiviate 3 times, filter to get filtrate, concentrate, water alcohol method is removed chlorophyll, centrifugal marriage supernatant, petroleum ether extraction, water intaking alcohol layer concentrates the back and goes up the D101 macroporous adsorbent resin, the dehydrated alcohol eluting gets Herba Agrimoniae extract, and active site is the Herba Agrimoniae flavone
Embodiment one: the glycosidase activity test: the weight percent proportioning of pharmaceutical composition is: 51 parts of Rhizoma Polygoni Cuspidati extracts, 24 parts of Folium Mori extracts, 25 parts of Herba Agrimoniae extracts.(wherein Rhizoma Polygoni Cuspidati extract 1: 11.73mg, Rhizoma Polygoni Cuspidati extract 2: 31.62mg, Rhizoma Polygoni Cuspidati extract 3: 7.65mg), Folium Mori extract 24mg, Herba Agrimoniae extract 25mg to take by weighing Rhizoma Polygoni Cuspidati extract 51mg according to the above ratio respectively, be dissolved in the 100mL water (adding a small amount of dimethyl sulfoxine hydrotropy), be made into the solution of 1mg/mL concentration.Assay method is according to (Pierre C such as Tremblay, Roland R Tremblay.The Journal of Clinical Chemistry, 1978,24:208～211) method, be substrate promptly with PNPG (4-Nitrobenzol-α-D-pyranglucoside), 0.1mol/LNa2CO3 be stop buffer, in the colorimetric determination of 400nm place.Said composition is to the suppression ratio of alpha-glucosidase and add and suppress the inhibition experiment that concerns between the dosage, and addition: 5,10,15,20,25,30 (μ L) record the alpha-glucosidase suppression ratio and suppress relation such as Fig. 1 between the dosage.
Embodiment two: the compositions proportioning that detects among the embodiment 1 is tested the inhibition of aldose reductase: add 20 μ L lithium sulfate (0.4mol/L) in 0.86mL phosphate buffer (pH6.5), 20 μ L DPNH I (10mmol/L) solution, 10 μ L inhibitor solutions (1mg/ml) and 60 μ L aldose reductase extracting solution, 37 ℃ are incubated 4min down, add 30 μ L DL-glyceraldehyde (10mmol/L) solution again, the variation of sweep record absorbance 6min under 340nm.Drawing said composition through experiment is 65.9% to the aldose reductase suppression ratio.And adopt three kinds of extracts that the aldose reductase suppression ratio is respectively separately: Rhizoma Polygoni Cuspidati extract 58.2%, Folium Mori extract 24.1%, Herba Agrimoniae extract 2.5%.
Embodiment three:
Post-prandial glycemia experiment: get 24 of normal mouses (first fasting is 10 hours before the experiment), be divided into 3 groups, get blood to be measured 0 blood glucose value constantly earlier before irritating stomach, use normal saline, acarbose (Glucobay) (100mg/kg), proportioning compositions and independent three kinds of extracts are irritated stomach (300mg/kg) among the embodiment 1 more respectively, finish the back and irritate starch fluid (5g/kg), each Mus was got blood in 0.5,1,2 hour respectively at irritating behind the starch fluid then.Measure the blood glucose value of blood that different time is got, the results are shown in Table 1.Fig. 2 is the design sketch of pharmaceutical composition to the influence of mice post-prandial glycemia.
Table 1 compositions is to the influence of normal mouse post-prandial glycemia content
| The normal saline group | The glucobay (acarbose) group | The compositions group | Rhizoma Polygoni Cuspidati extract | Folium Mori extract | Herba Agrimoniae extract | |
| Fasting glucose | 5.8 | 6.2 | 6.2 | 5.9 | 6.3 | 5.9 |
| 0.5 hour | 7.5 | 6.9 | 7.7 | 7.5 | 7.6 | 7.0 |
| 1 hour | 9.5 | 7.3 | 7.6 | 8.1 | 8.9 | 9.2 |
| 2 hours | 8.1 | 6.9 | 6.6 | 7.3 | 7.9 | 8.0 |
Embodiment four: successive administration experiment: the foundation of diabetic mice model: get 65 normal mouses and feed after three days, fasting 16h (drinking-water is not limit), behind the lumbar injection alloxan (200mg/kg), feed 72h, fasting was surveyed blood sugar concentration after four hours, chose blood glucose value the above person of 11.0mmol/L.Diabetic mice is divided into 4 groups, A, B, C, D group, wherein the A group is irritated glucophage (Glucophage, metformin hydrochloride) (100mg.kg
-1.d
-1), the B group is irritated acarbose (100mg.kg
-1.d
-1), the C group is irritated compositions (200mg.kg
-1.d
-1), the D group is irritated normal saline, and continuous medicine-filling is after 8 days, and the mouse blood sugar value is surveyed in fasting after the last perfusion after 4 hours, and blood extracting method is got blood, result such as table 2 for docking.
Table 2: the administration of compositions continuous several times is to the influence of blood glucose in diabetic mice content
| Group | Number of mice | Before the administration | After the administration |
| The A |
8 | 27.34 | 23.05 2 |
| The B acarbose | 8 | 26.74 | 21.94 2 |
| The |
8 | 26.52 | 16.96 2 |
| The D |
8 | 26.05 | 28.25 1 |
2 and 1 relatively: p＜0.001
Claims (3)
1. pharmaceutical composition that is used for the treatment of diabetes is characterized in that the constituent of said composition and weight percent proportioning thereof are as follows:
Rhizoma Polygoni Cuspidati extract 48-57%
Folium Mori extract 18-25%
Herba Agrimoniae extract 22-33%;
Wherein said Rhizoma Polygoni Cuspidati extract is that main active ingredient is that the Rhizoma Polygoni Cuspidati extract 1 of Rhizoma Polygoni Cuspidati tannic acid, main active ingredient are the Rhizoma Polygoni Cuspidati extract 2 of Rhizoma Polygoni Cuspidati resveratrol and Rhizoma Polygoni Cuspidati extract 3 that main active ingredient is the Rhizoma Polygoni Cuspidati emodin mixture with the weight ratio of 20-25: 60-65: 14-16; The main active ingredient of described Folium Mori extract is a flavones in mulberry leaves; The main active ingredient of described Herba Agrimoniae extract is the Herba Agrimoniae flavone;
The extracting method of described Rhizoma Polygoni Cuspidati extract 1 is: Rhizoma Polygoni Cuspidati rhizome coarse powder, 95% ethanol merceration, cooling bath filters, concentrating under reduced pressure gets extractum, use chloroform reflux extraction after adding water, back water liquid ethyl acetate extraction, the precipitation that ethyl acetate layer produces in the filtering extraction process, ethyl acetate layer NaOH aqueous solution extraction, the NaOH aqueous solution is regulated pH to 4 with rare HCl, and adding 5% aqueous gelatin solution must precipitate, precipitation adds 50% acetone solution, the centrifugal acetone soln that gets, acetone, water liquid ethyl acetate extraction are reclaimed in distilling under reduced pressure, ethyl acetate is reclaimed in the ethyl acetate layer distilling under reduced pressure, add the suitable quantity of water dissolving, the elimination precipitation, concentrate drying gets inhibitor crude product (orange-yellow powder), the inhibitor crude product is made into 10mg/ml goes up the HZ802 macroporous adsorbent resin, with 70% ethanol water eluting, collect active component, concentrate, dry orange-yellow inhibitor powder, main active is the Rhizoma Polygoni Cuspidati tannic acid;
The extracting method of described Rhizoma Polygoni Cuspidati extract 2 is: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (4: 6), and the some plate is followed the tracks of active substance, will have active substance partly to merge and cross silicagel column for the second time, mobile phase is constant, collect active component, drying gets white powder, and active site is the Rhizoma Polygoni Cuspidati resveratrol;
The extracting method of described Rhizoma Polygoni Cuspidati extract 3 is: the Rhizoma Polygoni Cuspidati rhizome is pulverized, 95% ethanol merceration 48 hours, leachate rotation evaporate to dryness, get extractum, with the water-soluble suspension that gets of extractum, after use petroleum ether, ethyl acetate and n-butanol extraction successively, ethyl acetate is gone up silicagel column mutually carry out normal-phase chromatography, mobile phase is ethyl acetate: petroleum ether (3: 7), and the some plate is followed the tracks of active substance, will have active substance partly to merge after silicagel column, mobile phase changes chloroform into, collect active component, drying gets pale yellow powder, and active site is the Rhizoma Polygoni Cuspidati emodin;
The extracting method of described Folium Mori extract is: the Folium Mori dry product, pulverize, and alcohol reflux 4 hours, 4000rpm gets supernatant, concentrates the back adding distil water, the centrifuging and taking supernatant, petroleum ether extraction gets water alcohol liquid.Last D101 adsorbent resin is washed to colourlessly, and the back is eluted to colourlessly with dehydrated alcohol, and concentrate drying promptly gets Folium Mori extract, and active site is a flavones in mulberry leaves;
The extracting method of described Herba Agrimoniae extract is: the Herba Agrimoniae coarse powder, 40% ethanol lixiviate 3 times, filter to get filtrate, concentrate, water alcohol method is removed chlorophyll, centrifugal marriage supernatant, petroleum ether extraction, water intaking alcohol layer concentrates the back and goes up the D101 macroporous adsorbent resin, the dehydrated alcohol eluting gets Herba Agrimoniae extract, and active site is the Herba Agrimoniae flavone.
2. a kind of application of pharmaceutical composition in the preparation hypoglycemic drug that is used for the treatment of diabetes according to claim 1.
3. as a kind of application of pharmaceutical composition in preparation treatment diabetes medicament that is used for the treatment of diabetes according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100272736A CN100356943C (en) | 2005-09-09 | 2005-09-09 | Medicinal composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100272736A CN100356943C (en) | 2005-09-09 | 2005-09-09 | Medicinal composition for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1730046A CN1730046A (en) | 2006-02-08 |
| CN100356943C true CN100356943C (en) | 2007-12-26 |
Family
ID=35962491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100272736A Expired - Fee Related CN100356943C (en) | 2005-09-09 | 2005-09-09 | Medicinal composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100356943C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000169A (en) * | 2010-10-28 | 2011-04-06 | 广东工业大学 | Hairyvein agrimony extract and application thereof in preparation of medicament for treating diabetes mellitus |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991670A (en) * | 2010-10-28 | 2011-03-30 | 广东工业大学 | Alpha-gluconase activity inhibiter and application thereof in preparation of diabetic medicament |
| CN107744143A (en) * | 2017-10-25 | 2018-03-02 | 湖南共为特殊医学配方食品有限公司 | Diabetes full nutrition formula food |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555865A (en) * | 2004-01-12 | 2004-12-22 | 季长春 | Medicine for treating diabetes |
-
2005
- 2005-09-09 CN CNB2005100272736A patent/CN100356943C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555865A (en) * | 2004-01-12 | 2004-12-22 | 季长春 | Medicine for treating diabetes |
Non-Patent Citations (1)
| Title |
|---|
| 植物药治疗糖尿病的研究概况 车今智.中草药，第1卷第35期 2004 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000169A (en) * | 2010-10-28 | 2011-04-06 | 广东工业大学 | Hairyvein agrimony extract and application thereof in preparation of medicament for treating diabetes mellitus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1730046A (en) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Progress in the discovery of naturally occurring anti-diabetic drugs and in the identification of their molecular targets | |
| Aba et al. | Mechanisms of actions of some bioactive anti-diabetic principles from phytochemicals of medicinal plants: A review | |
| GHOLAM et al. | The inhibitory effect of some Iranian plants extracts on the alpha glucosidase | |
| Kumar et al. | Anti-diabetic activity of Syzygium cumini and its isolated compound against streptozotocin-induced diabetic rats | |
| Nalamolu et al. | Effect of chronic administration of Boerhaavia diffusa Linn. leaf extract on experimental diabetes in rats | |
| Eddouks et al. | Potent hypoglycaemic activity of the aqueous extract of Chamaemelum nobile in normal and streptozotocin-induced diabetic rats | |
| Wang et al. | A survey of Chinese herbal ingredients with liver protection activities | |
| CN100506259C (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN108440292A (en) | Different sequence Chinese tallow tree element A-H and its pharmaceutical composition and its application | |
| Chehri et al. | Anti-diabetic potential of Urtica Dioica: current knowledge and future direction | |
| CN100356943C (en) | Medicinal composition for treating diabetes | |
| Qiu et al. | The leaves of Cyclocarya paliurus: A functional tea with preventive and therapeutic potential of type 2 diabetes | |
| CN101991567A (en) | Application of three biflavone monomer components extracted from ginkgo leaves in preparing medicament of alpha-glucosidase inhibitor | |
| CN109078134A (en) | It is a kind of that not only there is Chinese medicine composition and preparation method thereof that is anti-oxidant but also can reduce gout patients serum Uric Acid Concentration | |
| CN1565467B (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN104337884A (en) | Medicine composition for preventing and/or treating diabetes and complication of diabetes | |
| CN101156908B (en) | Application of argentina anserina extractive in preparation of alpha glycosidase enzymes inhibitors | |
| CN101040917A (en) | Traditional Chinese medicinal composition with reducing-blood-sugar activity | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102579587B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| Mishra et al. | Hypoglycemic activity of methanol fraction of Tectona grandis (Linn) bark in experimental rat models | |
| CN101869663B (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| Sisay et al. | Glinus lotoides linn. Seed extract as antidiabetic agent: In vitro and in vivo anti-glucolipotoxicity efficacy in Type-II diabetes mellitus | |
| Satpathy | Application of some medicinal plants and their constituents in the treatment of diabetes mellitus | |
| Abbas et al. | Phytochemicals in the Management of Diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071226 Termination date: 20100909 |